We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
-12.02%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$760M
AUM Growth
+$89.2M
Cap. Flow
+$192M
Cap. Flow %
25.21%
Top 10 Hldgs %
39.48%
Holding
222
New
36
Increased
135
Reduced
20
Closed
26

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$9.39M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$8.96M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$7.48M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$5.93M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$5.63M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$10.1M
2
BCYC
Bicycle Therapeutics
BCYC
+$6.27M
3
BIIB icon
Biogen
BIIB
+$6.18M
4
GOSS icon
Gossamer Bio
GOSS
+$3.78M
5
IBB icon
iShares Biotechnology ETF
IBB
+$3.67M

Sector Composition

Rank Sector Weight
1 Healthcare 42.6%
2 Consumer Staples 0.27%
3 Technology 0.24%
4 Financials 0.1%
5 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAGE
26
DELISTED
Sage Therapeutics
SAGE
$8.27M 1.09%
+249,907
New +$9.39M
PCVX icon
27
Vaxcyte
PCVX
$7.86B
$7.63M 1%
315,991
+20,880
+7% +$456K
TCON
28
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$7.48M 0.98%
142,162
+7,606
+6% +$382K
XENE icon
29
Xenon Pharmaceuticals
XENE
$6.08B
$7.32M 0.96%
239,441
+60,303
+34% +$1.81M
BHVN
30
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$7.11M 0.94%
+60,000
New +$7.48M
SRRA
31
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$6.98M 0.92%
217,915
-351,114
-62% -$10.1M
GOSS icon
32
Gossamer Bio
GOSS
$82.8M
$6.73M 0.89%
775,315
-391,618
-34% -$3.78M
VRTX icon
33
Vertex Pharmaceuticals
VRTX
$120B
$6.52M 0.86%
+25,000
New +$5.93M
RIGL icon
34
Rigel Pharmaceuticals
RIGL
$685M
$6.39M 0.84%
213,713
+169,777
+386% +$4.6M
KRTX
35
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$6.34M 0.83%
+50,000
New +$5.63M
BLU
36
DELISTED
BELLUS Health Inc.
BLU
$6.28M 0.83%
913,327
+863,327
+1,727% +$5.56M
IMTX icon
37
Immatics
IMTX
$1.2B
$6.24M 0.82%
781,388
+43,842
+6% +$400K
MCRB icon
38
Seres Therapeutics
MCRB
$45.2M
$5.99M 0.79%
42,031
+2,236
+6% +$344K
SCPH
39
DELISTED
scPharmaceuticals
SCPH
$5.51M 0.72%
970,098
+68,736
+8% +$338K
LKFT
40
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.79B
$5.41M 0.71%
86,865
– –
AMLX icon
41
Amylyx Pharmaceuticals
AMLX
$2.2B
$5.1M 0.67%
+396,654
New +$8.96M
AMGN icon
42
Amgen
AMGN
$206B
$4.84M 0.64%
+20,000
New +$4.6M
RCUS icon
43
CALL
Arcus Biosciences
RCUS
$3.48B
$4.73M 0.62%
+150,000
New +$5.03M
BCYC
44
PUT
Bicycle Therapeutics
BCYC
$269M
$4.68M 0.62%
+106,600
New +$4.98M
KZR
45
CALL
DELISTED
Kezar Life Sciences
KZR
$4.67M 0.61%
28,080
+11,150
+66% +$1.6M
PFE icon
46
Pfizer
PFE
$142B
$4.14M 0.54%
+80,000
New +$4.15M
BPMC
47
CALL
DELISTED
Blueprint Medicines
BPMC
$4.09M 0.54%
+64,000
New +$4.59M
BMRN icon
48
BioMarin Pharmaceuticals
BMRN
$11.5B
$3.86M 0.51%
+50,000
New +$4.18M
CMRX
49
DELISTED
Chimerix, Inc.
CMRX
$3.85M 0.51%
841,203
+45,793
+6% +$255K
PTGX icon
50
CALL
Protagonist Therapeutics
PTGX
$8.7B
$3.81M 0.5%
160,700
+33,800
+27% +$952K
1
2
3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Ikarian Capital held 222 positions worth $760M, up 13% from $671M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Ikarian Capital deployed $192M of net new capital in Q1 2022, opening 36 new positions and adding to 135 existing holdings. Its largest new stake was Sage Therapeutics: 249,907 shares worth $8.27M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 51% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Sierra Oncology, Inc. Common Stock, an estimated $10.1M trimmed.

  • Ikarian Capital's largest Q1 2022 buy was Sage Therapeutics: 249,907 shares worth $8.27M.
  • Ikarian Capital added most to BELLUS Health Inc. in Q1 2022, an estimated $5.56M increase.
  • Ikarian Capital's biggest Q1 2022 reduction was Sierra Oncology, Inc. Common Stock, cutting an estimated $10.1M.
  • Ikarian Capital fully exited iShares Biotechnology ETF in Q1 2022, selling an estimated $3.67M.
  • Ikarian Capital's ten largest holdings make up 39% of its $760M portfolio in Q1 2022.
  • Ikarian Capital opened 36 new positions and closed 26 in Q1 2022.
  • Ikarian Capital's portfolio value rose 13% quarter-over-quarter to $760M.

Based on Ikarian Capital's 13F filing for Q1 2022, filed 13 May 2022.